FDA Recall Open, Classified

directCHECK ACT-LR whole blood quality control, level 2 Model/Catalog Number: DCGLR-2

Recall: Z-2460-2026 · Initiated April 30, 2026

Recall

Recall Number
Z-2460-2026
Event Number
98979
Firm
Accriva Diagnostics, Inc.
FEI Number
2250033
Product Code
GGN
Status
Open, Classified
Root Cause
Process control
Initiated
April 30, 2026
Posted
June 16, 2026
Address
6260 Sequence Dr, San Diego, CA, 92121-4358

Description

directCHECK ACT-LR whole blood quality control, level 2 Model/Catalog Number: DCGLR-2

Reason

Assayed Whole blood control contains labeling with incorrect performance range.

Action

On May 8, 2026 Accriva Diagnostics, issued a Urgent Medical Device Recall Notification to affected consignees via E-Mail.. Accriva asked consignees to take the following actions: 1. Please forward this communication to those within your organization who need to become aware 2. Forward the enclosed customer notification to all other organizations where affected devices may have been transferred to. 3. Forward the enclosed customer notification to those in your organization that are responsible for performing quality control testing and/or supervise testing. 4. Please check your inventory to determine if you have any boxes of directCHECK Whole BloodControls. If you have this product in stock, do NOT use. 5. Please destroy all impacted boxes and document on the enclosed form. 6. Please read the instructions on the Tracking Form and complete and return the form to Accriva Diagnostics, Inc. 7. If you have any technical questions, please contact Technical Services at 1-800-678-0710 Option 3 or e-mail [email protected].

Distribution

Worldwide - US Nationwide distribution including in the states of AL, AR, AZ, CA, FL, GA, ID, IL, IN, KY, MA, MD, MI, MN, MO, MT, NC, NJ, NM, NY, OH, OK, PA, SC, TN, TX, VA, VT, WA, WI, WV and the countries of Canada, Hong Kong, Spain.

Quantity

6060